Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
3.200
+0.160 (5.26%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Tvardi Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025 FY 2024 FY 2023 FY 2022
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22
Net Income
-18.21-29.4-17.35-20.54
Depreciation & Amortization
0.10.10.10.09
Loss (Gain) From Sale of Investments
-0.2--0.19-0.36
Stock-Based Compensation
1.40.320.310.25
Other Operating Activities
-7.092.040.050.03
Change in Accounts Payable
0.925.57-1.012.2
Change in Other Net Operating Assets
-0.413.07-2.950.47
Operating Cash Flow
-23.5-18.31-21.04-17.87
Capital Expenditures
----0.05
Investment in Securities
-10.08-22.47-21.95
Investing Cash Flow
-10.08-22.47-22
Long-Term Debt Issued
-28.3--
Net Debt Issued (Repaid)
-28.3--
Issuance of Common Stock
0.530.0100
Other Financing Activities
22.17-1.3--
Financing Cash Flow
22.72700
Net Cash Flow
-10.888.71.43-39.86
Free Cash Flow
-23.5-18.31-21.04-17.92
Free Cash Flow Per Share
-3.02-7.11-3.30-2.81
Levered Free Cash Flow
-15.22-6.91-15.13-
Unlevered Free Cash Flow
-15.22-6.91-15.13-
Change in Working Capital
0.518.64-3.962.67
Source: S&P Capital IQ. Standard template. Financial Sources.